Safety Study in Adolescent and Adult Patients With Asthma
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be
able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in
a double-blinded manner.